Article Text

Download PDFPDF

Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
Free
  1. Xianming Huang1,
  2. Jian Gong2,
  3. Dan Ye3,
  4. Van Nguyen4,
  5. Shen Yin4,
  6. Rich Archer2,
  7. Chris Hughes5,
  8. Rolf Brekken1,
  9. Jeff Hutchins6,
  10. Alan Schroit3 and
  11. Bruce Freimark2
  1. Aff1 grid.267313.20000000094827121Department of PharmacologyUT Southwestern Medical Center Dallas TX USA
  2. Aff2 grid.430202.7Peregrine Pharmaceuticals, Inc Tustin CA USA
  3. Aff3 grid.267313.20000000094827121Department of SurgeryUniversity of Texas, Southwestern Medical Center at Dallas TX USA
  4. Aff4 grid.430202.7Peregrine Pharmaceuticals, Inc USA
  5. Aff5 grid.266093.80000000106687243University of California Irvine CA USA
  6. Aff6 grid.430202.7Department of Clinical AffairsPeregrine Pharmaceuticals Inc. Tustin CA USA

Statistics from Altmetric.com

Meeting abstracts

Phosphatidylserine (PS) is an upstream immune checkpoint that drives global immunosuppression. Previous work has shown that PS targeting agents can override PS-driven immunosuppression and re-program the tumor microenvironment from immunosuppressive to immunosupportive, break tumor immune tolerance, and elicit potent de novo antitumor T-cell immunity. In the present study, the antitumor effect of the combination of a PS-targeting antibody with antibodies that inhibit the downstream immune checkpoints PD-1 or CTLA-4 antibody in the K1735 mouse melanoma model was examined. Tumor-bearing mice were treated with each antibody alone or the combination at 5 to 10 mg/kg, twice a week. Combination therapy potently suppressed tumor growth and improved overall survival compared to single agent treatment. Flow cytometry revealed that combination therapy induced the highest ratio of tumor-infiltrating immune effector to suppressor cells. Importantly, combination treatment also significantly decreased the levels of myeloid-derived suppressor cells (MDSC) in the spleen. In addition, inhibition of PS and PD-1 or CTLA-4 resulted in significantly more IL-2 and IFNg-secreting splenic CD4+ and CD8+ T cells than any single agent treatment. Finally, combined immune checkpoint blockade did not induce any observable toxicity following multiple treatment doses. In summary, our findings demonstrate that the combination of antibody-mediated PS blockade with an inhibition of established immune checkpoints (e.g., PD-1 and CTLA-4) represents a promising strategy for cancer immunotherapy.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.